Modifying gap junction communication in cancer therapy

Area of Science:

• Cancer Biology
• Molecular Oncology
• Drug Discovery

Background:

• Gap junction intercellular communication (GJIC) is vital for drug delivery in tumors.
• Pro-drug activation therapy, like Ganciclovir triphosphate (GCV-TP), leads to cancer cell death.
• Histone deacetylase inhibitors (HDACi) and All Trans Retinoic Acid (ATRA) can modulate GJIC.

Purpose of the Study:

• To enhance GJIC using HDACi and ATRA for improved drug delivery.
• To investigate the combined effects of HDACi, ATRA, and Dexamethasone (DXM) on GJIC and cancer cell cytotoxicity.
• To abrogate the detrimental effects of DXM on GJIC when used in combination therapy.

Main Methods:

• Utilized NT8E and HeLa cell lines, treated with Valproic Acid (VPA), 4 Phenylbutyrate (4PB), ATRA, and DXM.
• Assessed Connexin (CX 43, 26, 32) and E-Cadherin expression via Western blotting and qRT-PCR.
• Evaluated GJIC competence, cytotoxicity, and cell death mechanisms in vitro.

Main Results:

• HDACi (VPA, 4PB) and ATRA significantly enhanced GJIC (30-54%) and increased cytotoxicity (60%).
• Connexin and E-Cadherin expression patterns were modulated by HDACi, DXM, and ATRA.
• Combination therapy abrogated DXM's inhibitory effect on GJIC when combined with VPA or ATRA.

Conclusions:

• Enhanced GJIC via HDACi and ATRA boosts anti-cancer cytotoxicity.
• Combination therapy with ATRA or VPA can overcome DXM-induced inhibition of GJIC.
• This strategy holds potential for improving pro-drug activation therapies in cancer treatment.